REFERENCES

• WesnesKA.The effects of psychotropic drugs on human behavior.Mod Probi Pharmacopsychiatry.1977123758
   PubMedGoogle Scholar
• WesnesKA.WarburtonDM.The effects of cigarette smoking and nicotine tablets upon human attention. In: Thornton RE, ed.Smoking Behavior: Physiological and Psychoiogicai influences. London, UK: Churchill-Livingstone1978131147
   Google Scholar
• SimpsonPM.SurmonDJ.WesnesKA.WilcockGR.The Cognitive Drug Research computerized assessment system for demented patients: a validation study.Int J Geriatr Psychiatry.1991695102
   Web of Science ®Google Scholar
• SimpsonPM.WesnesKA.ChristmasL.A computerized system for the assessment of drug-induced performance changes in young elderly or demented populations.Br J Clin Pharmacol.198927711712
   Web of Science ®Google Scholar
• EdwardsJ.WesnesKA.WarburtonDM.GaleA.ERP evidence of more rapid stimulus evaluation following cigarette smoking.Addict Behav.1983101131264013861
   PubMed Web of Science ®Google Scholar
• McClellandGR.WesnesKA.Reaction times and the evoked potential.Eur J Clin Invest.199525(suppl 2)A64
   Google Scholar
• McClellandGR.WesnesKA.The relationships between P300 and cognitive processing in simple and choice reaction tasks.J Psychopharmacol.19959(suppl)A39
   Google Scholar
• WesnesKA.MeulenbergO.VermeijB.et al.The acute cognitive effects of amitriptyline, hydroxyzine and lorazepam in volunteers.J Psychopharmacol.199610(suppl)A51
   Google Scholar
• PincockC.DaviesG.WesnesKA.The effects of training on the quality of performance on computerized cognitive tasks.J Psychopharmacol.199711(suppl)A57
   Google Scholar
• WardT.WesnesKA.Validity and utility of the CDR computerized cognitive assessment system: a review following 15 years of use.J Psychopharmacol199913(suppl A)A25
   Google Scholar
• WesnesKA.HildebrandK.MohrE.Computerized cognitive assessment. In: Wilcock GW, Bucks RS, Rocked K, eds.Diagnosis and Management of Dementia: A Manual for Memory Disorders Teams. Oxford, UK: Oxford University Press1999124136
   Google Scholar
• WesnesKA.MountRH.StephensonN.LocktonJA.RolanP.A comparison of computerized and non-computerized cognitive assessments.J Psychopharmacol.199610(suppl)A29
   Google Scholar
• WesnesKA.O'NeillST.Benzodiazepines affect simple not choice reaction time in a choice reaction time task.J Psychopharmacol.199610(suppl)A52
   Google Scholar
• WesnesKA.SimpsonP.WhiteL.PinkerS.The Cognitive Drug Research computerized assessment systems for elderly, AAMI and demented patients.J Psychopharmacol.19926108
   Google Scholar
• WesnesKA.SimpsonPM.ChristmasL.The assessment of human information processing abilities in psychopharmacology. In: Hindmarch I, Stonier PD, eds.Human Psychopharmacology: Measures and Methods. Vol 1. Chichester, UK: Wiley19877992
   Google Scholar
• JonesS.JensenNO.OliverS.WesnesKA.Cognitive effects of single doses of ME3127, a novel anxiolytic in volunteers.J Psychopharmacol.199913(suppl A)A27
   Google Scholar
• McEwenJ.WesnesKA.RapeportWG.WilliamsS.The cognitive effects of single and multiple doses of UK 76,654, a selective M3 muscarinic antagonist in healthy volunteers.Eur J Clin Invest.199525(suppl 2)A64
   Google Scholar
• Russell-DuffK.JensenNO.MooneyP.WesnesKA.Cognitive effects of NS2389, a serotonin reuptake inhibitor, in healthy volunteers.J Psychopharmacol.199913(suppl A)A27
   Google Scholar
• PincockC.JensenNO.OliverS.WesnesKA.JonesS.Cognitive effects of multiple doses of ME3127, a novel anxiolytic, in volunteers.J Psychopharmacol.199913(suppl A)A27
   Google Scholar
• HollandRL.WesnesKA.DietrichB.Single-dose human pharmacology of umespirone.Eur J Clin Pharmacol.1994464614687957544
   PubMed Web of Science ®Google Scholar
• WilcoxC.WesnesKA.HeiserJ.SimpsonP.KatzB.HappyJ.A doubleblind, eight-way crossover comparison of abecarnil, lorazepam and placebo alone and after a single dose of alcohol, on psychometric performance in healthy volunteers.Psychopharmacol Bull.199632536
   Google Scholar
• WesnesKA.de KoningP.DietrichB.A comparison of the cognitive effects of DU 29894, sulpiride, haloperidol and a selective 5HT1A agonist in normal volunteers.Eur J Clin Invest.199525(suppl 2)A64
   Google Scholar
• KleinbloesemC.JaquetF.HesseWH.et alCNS and cardiovasculareffects of RWJ-37796, a new antipsychotic, in healthy male subjects.J Clin Pharmacol.1994341027
   Google Scholar
• KleinbloesemCH.Jaquet-MüllerF.Al-HamdanY.et al.Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men.Clin Trials Ther.199659675685
   Web of Science ®Google Scholar
• WesnesKA.McClellandG.Acute effects of cilazapril and atenolol on cognitive function and EEG in volunteers.J Psychopharmacol.199610(suppl)A51
   Google Scholar
• PincockC.WesnesKA.BeuzenJN.TaylorN.WoodA.The effects of olanzapine and haloperidol on cognitive function in healthy elderly volunteers.Proc Br Psychol Soc.1999712
   Google Scholar
• LegangneuxE.McEwenJ.WesnesKA.et al.The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers.J Psychopharmacol.20001416417110890311
   PubMed Web of Science ®Google Scholar
• WesnesKA.SimpsonP.ChristmasL.AnandR.McClellandGR.The cognitive effects of moclobemide and trazodone alone and in combination with ethanol in healthy elderly volunteers.Br J Clin Pharmacol.198927647648
   Web of Science ®Google Scholar
• LocktonJA.ColeG.HammersleyM.WesnesKA.Cognitive function is unaffected by remacemide at therapeutically relevant single doses.J Psychopharmacol.199812(suppl A)A41
   Google Scholar
• LocktonJA.WesnesKA.YeatesN.RolanP.DiggoryG.Remacemide does not affect cognitive function following multiple dosing.J Psychopharmacol.199812(suppl A)A41
   Google Scholar
• BirchB.CurranHV.The differential effects of flumazenil on the psychomotor and amnesic actions of midazolam.J Psychopharmacol.199042934
   PubMedGoogle Scholar
• AyreG.ReedC.ScholeyA.NeaveN.GirdlerNWesnesKA.The acute dose-dependent cognitive effects of flumazenil in healthy volunteers.J Psychopharmacol.199913(suppl A)A28
   Google Scholar
• TempletonL.BarkerA.WesnesKA.WilkinsonD.A double-blind, placebo-controlled trial of intravenous flumazenil in Alzheimer's disease.Hum Psychopharmacol.199914239245
   Web of Science ®Google Scholar
• O'NeillWM.HanksGW.WhiteL.SimpsonP.WesnesK.The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects.Eur J Clin Pharmacol.1995484474538582462
   PubMed Web of Science ®Google Scholar
• HanksGW.O'NeillWM.SimpsonP.WesnesK.The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects.Eur J Clin Pharmacol.1995484554608582463
   PubMed Web of Science ®Google Scholar
• O'NeillWM.HanksGW.SimpsonP.FallonMT.JenkinsE.WesnesK.The cognitive and psychomotor effects of morphine in healthy subjects. A randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine and lorazepam and placebo.Pain.20008520921510692620
   PubMed Web of Science ®Google Scholar
• BrookeC.EhnhageA.FranssonB.et al.The effects of intravenous morphine on cognitive function in healthy volunteers.J Psychopharmacol.199812(suppl A)A45
   Google Scholar
• WesnesKA.WarburtonDM.A comparison of flurazepam and temazepam in terms of sleep quality and residual effects on performance.Neuropsychobiology.1984112552596149491
   PubMed Web of Science ®Google Scholar
• WesnesKA.WarburtonDM.Effects of temazepam on sleep quality and subsequent mental efficiency under normal sleeping conditions and following delayed sleep onset.Neuropsychobiology.1986151871912878389
   PubMed Web of Science ®Google Scholar
• WesnesKA.WarburtonDM.Stress, drugs and performance. In: Hockey GRJ, ed.Stress and Fatigue in Human Performance. London, UK: Wiley1983203244
   Google Scholar
• WesnesKA.GudgeonA.A comparison of the profiles of cognitive impairment produced by alcohol, scopolamine and lorazepam.J Psychopharmacol.19959(suppl)A13
   Google Scholar
• KastbergH.JansenJA.ColeG.WesnesKA.Tiagabine: absence of kinetic or dynamic interactions with ethanol.Drug Metab Drug Interact.199814259273
   PubMedGoogle Scholar
• WesnesKA.LocktonA.RolanP.StephensonN.PincockC.Volunteer study of the potential interaction between remacemide 300 mg and alcohol (0.7 g/kg).J Psychopharmacol.199711(suppl)A59
   Google Scholar
• WesnesKA.GarrattC.WickensM.GudgeonA.OliverS.Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers.Br J Clin Pharmacol.20004911011710671904
   PubMed Web of Science ®Google Scholar
• SemosML.FitzpatrickK.JonesRW.MannJB.RamezaniE.WesnesKAAbsence of interaction between SB-202026 and alcohol in healthy elderly volunteers.J Psychopharmacol.199812(suppl A)A40
   Google Scholar
• van HartenJ.StevensL.RaghoebarM.HollandR.WesnesK.CournotA.Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function.Clin Pharmacol Ther.1992524274351424416
   PubMed Web of Science ®Google Scholar
• WesnesKA.SimpsonP.ChristmasL.AnandR.McClellandGR.The effects of moclobemide on cognition.J Neural Transm.19892991102
   Google Scholar
• RapeportWG.MuirheadDC.WilliamsSA.CrossM.WesnesK.Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin.J Clin Psychiatry.19965724288617708
   PubMed Web of Science ®Google Scholar
• RapeportWG.WilliamsSA.MuirheadDC.DewlandPM.TannerT.WesnesK.Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine.J Clin Psychiatry.19965720238617707
   PubMed Web of Science ®Google Scholar
• WilliamsSA.WesnesKA.OliverSD.RapeportWG.Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.J Clin Psychiatry.1996577118617710
   PubMed Web of Science ®Google Scholar
• van HartenJ.WesnesKA.StrobelW.No kinetic or dynamic interaction between flesinoxan and fluoxetine.Eur Neuropsychopharmacol.19966(suppl 3)40
   Google Scholar
• WesnesKA.SimpsonPM.JanssonB.GrahnénA.WeimannHJ.KüppersH.Moxonidine and cognitive function: interactions with moclobemide and lorazepam.Eur J Clin Pharmacol.1997523513589272403
   PubMed Web of Science ®Google Scholar
• WesnesKA.WardT.Treatment of age-associated memory impairment. In: Qizilbash N, Schneider L, Chuif H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T, eds.Evidence-Based Dementia: A Practical Guide to Diagnosis and Management (with internet updates). Oxford, UK: Blackwell Science Publications. 2001. In press.
   Google Scholar
• WesnesKA.WarburtonDM.The effects of smoking on rapid information processing performance.Neuropsychobiology.198392232296646394
   PubMed Web of Science ®Google Scholar
• WesnesKA.WarburtonDM.The effects of cigarettes of varying yield on rapid information processing performance.Psychopharmacology.1984823383426427826
   PubMed Web of Science ®Google Scholar
• ParrottA.GarnhamN.WesnesKA.PincockP.Cigarette smoking and abstinence: comparative effects upon cognitive task performance and mood state over 24 hours.Hum Psychopharmacol.199611391400
   Web of Science ®Google Scholar
• WesnesKA.SimpsonPM.ChristmasL.Puff by puff profiles of performance, mood and acceptability in low and non-low tar smokers. In: Rand MJ, Thurau K, eds.The Pharmacology of Nicotine. Oxford, UK: IRL Press1988406408
   Google Scholar
• WesnesKA.ParrottA.Smoking, nicotine and human performance. In: Smith A, Jones D, eds.Handbook of Human Performance. Vol 2. London, UK: Academic Press1992127167
   Google Scholar
• WesnesKA.Nicotine increases mental efficiency, but how? In: Martin WR, Van Loon GR, Iwamoto ET, Davis DL, eds.Tobacco Smoke and Nicotine: A Neurobiological Approach. New York: Plenum19876381
   Google Scholar
• WesnesKA.WarburtonDM.RevellA.Work and stress as motives for smoking. In: Gumming G, Bonsignore G, eds.Smoking and the Lung. New York, NY: Plenum1984233249
   Google Scholar
• WesnesKA.WarburtonDM.MatzB.The effects of nicotine on stimulus sensitivity and response bias in a visual vigilance task.Neuropsychobiology.1983941446888708
   PubMed Web of Science ®Google Scholar
• WesnesKA.WarburtonDM.Effects of scopolamine and nicotine on human rapid information processing performance.Psychopharmacology.1984821471506425892
   PubMed Web of Science ®Google Scholar
• WesnesKA.WarburtonDM.Nicotine, smoking and human performance.Pharmacol Ther.1983211892086353441
   PubMed Web of Science ®Google Scholar
• ParrottAC.WinderG.Nicotine chewing gum (2 mg, 4 mg) and cigarette smoking: comparative effects upon vigilance and heart rate.Psychopharmacology.1989972572612498936
   PubMed Web of Science ®Google Scholar
• ParrottAC.CraigD.Cigarette smoking and nicotine gum (0 mg, 2 mg, 4 mg): effects upon different aspects of visual attention.Neuropsychobiology.19922534431603292
   PubMed Web of Science ®Google Scholar
• ParrottAC.CraigD.HainesM.WinderG.Nicotine polacrilex gum and sustained attention. In: Adlkofer F, Thurau K, eds.Effects of Nicotine on Biological Systems. Basel, Switzerland: Birkhauser Press1990
   Google Scholar
• ScholeyAB.ReilyC.WesnesKA.Effects of nicotine administered via an inhaler on cognitive performance in smokers and never smokers.J Psychopharmacol.199913(suppl A)A25
   Google Scholar
• JonesM.The effects of caffeine and smoking upon mood and cognitive performance in day workers.Proc Br Psychol Soc.1999712
   Google Scholar
• JonesMEE.ParrottA.WesnesKA.The effects of caffeinated and decaffeinated beverages on cognitive performance, heart rate and mood in shift workers.J Psychopharmacol.199812(suppl A)A42
   Google Scholar
• ScholeyAB.ChandlerCEK.WesnesKA.Caffeine and cognitive performance: interactions between actual and informed caffeine content.J Psychopharmacol.199913(suppl A)A53
   Google Scholar
• MorrisPG.O'CarrollR.Cognitive effects of glucose administration.Proc Br Psychol Soc.1999712
   Google Scholar
• MossM.ScholeyA.WesnesK.Oxygen and cognition: a selective or global effect?Proc Br Psychol Soc.19975134
   Google Scholar
• ScholeyAB.FordC.AyreGA.WesnesKA.Effects of glucose administration and emotional content of words on heart rate and emotional memory.J Psychopharmacol.199913(suppl A)A28
   Google Scholar
• MossMC.ScholeyA.NeaveN.WesnesKA.Cognitive enhancement and physiological responses following oxygen administration.J Psychopharmacol.199711(suppl)A61
   Google Scholar
• MossMC.ScholeyAB.WesnesKA.Oxygen administration selectively enhances cognitive performance in healthy young adults: a placebo-controlled double-blind crossover study.Psychopharmacology.199813827339694523
   PubMed Web of Science ®Google Scholar
• ScholeyA.MicklethwaiteK.MitchellD.MossM.WesnesKA.Nicotine and oxygen differentially affect performance on tasks of incidental learning and attention.Proc Br Psychol Soc.19997110
   Google Scholar
• ScholeyA.MossM.WesnesKA.Is oxygen a smart drug?Proc Br Psychol Soc.1997558
   Google Scholar
• ScholeyAB.MossMC.NeaveN.WesnesK.Cognitive performance, hyperoxia and heart rate following oxygen administration in healthy young adults.Physiol Behav.19996778378910604851
   PubMed Web of Science ®Google Scholar
• ScholeyAB.MossMC.NeaveN.WesnesKA.Oxygen administration enhances cognitive performance: physiological responses and effect of cognitive load. A selective effect.Eur J Neurosci.199810(suppl 10)251
   Web of Science ®Google Scholar
• ScholeyAB.MossMC.WesnesKA.Oxygen and cognitive performance: the temporal relationship between hyperoxia and enhanced memory.Psychopharmacology.19981401231269862412
   PubMed Web of Science ®Google Scholar
• MossMC.ScholeyAB.NeaveN.StubbsP.WesnesKA.Oxygen administration and cognitive performance in the elderly: a case of selective enhancement.J Psychopharmacol.199812(suppl A)A41
   Google Scholar
• MossMC.ScholeyAB.NeaveN.WesnesKA.Oxygen administration selectively enhances cognitive performance in the elderly.Proc Br Psychol Soc.19997110
   Google Scholar
• JonesS.JensenNO.OliverS.WesnesKA.First in man cognitive effects of NS2330, a novel monoamine reuptake inhibitor, in volunteers.J Psychopharmacol.199913(suppl A)A26
   Google Scholar
• WillsK.JensenNO.OliverS.WesnesKA.Cognitive effects of NS2330, a novel monoamine reuptake inhibitor, in volunteers.J Psychopharmacol.199913(suppl A)A27
   Google Scholar
• BosworthJ.JensenNO.OliverS.WesnesKA.First cognitive effects of NS2359, a noradrenaline, dopamine and serotonin reuptake inhibitor, in volunteers.J Psychopharmacol.199913(suppl A)A26
   Google Scholar
• KitagawaH.MoriyamaA.TakenouchiT.WesnesKA.KramerW.ClodyDE.Phase I studies of GTS-21 to assess the safety, tolerability, PK and effects on measures of cognitive function in normal volunteers.Neurobiol Aging.199819(suppl 2)S182
   Google Scholar
• WesnesKA.SimpsonPM.ThompsonS.et al.Cognitive enhancement with physostigmine in young volunteers. Annual Meeting of the British Association for Psychopharmacology 1994; Cambridge, UK. 7
   Google Scholar
• Woodruff-PakDS.JaegarME.GolmanC.WesnesKA.Relationships among age, CS-US interval and neuropsychological test performance.Neuropsychology.1999139010210067780
   PubMed Web of Science ®Google Scholar
• de WildeHJG.WesnesKA.NeumanE.et al.Cognitive enhancing effects of S12024-2 during repeated oral administration at 4 dose levels in 36 healthy elderly volunteers.Eur J Clin Invest.199525(suppl 2)A65
   Google Scholar
• SiegfriedK.First clinical impressions with an ACTH analogue (HOE 427) in the treatment of Alzheimer's disease.Ann N Y Acad Sci.1991640260283
   Web of Science ®Google Scholar
• van HartenJ.OlffM.WesnesKA.StrobelW.Flesinoxan improves cognition in the elderly.Eur Neuropsychopharrnacol.19966(suppl 3)186
   Google Scholar
• AnandR.WesnesKA.Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans. In: Wurtman RJ, Corkin S, Growdon JH, Ritter-Walker E, eds.Alzheimer's Disease. New York, NY: Raven Press1990261268
   Google Scholar
• WesnesKA.WarburtonDM.Effects of scopolamine on stimulus sensitivity and response bias in a visual vigilance task.Neuropsychobiology.198391541576621852
   PubMed Web of Science ®Google Scholar
• EbertU.Influence of various drugs on quantitative electroencephalogram and cognitive function - selected study results.Eur J Clin Pharmacol.199650520
   Google Scholar
• Learned-CoughlinSM.WesnesKA.MountRM.VenitzJ.CNS pharmacodynamics of scopolamine in healthy young male and female volunteers.J Psychopharmacol.199711(suppl)A58
   Google Scholar
• ParrottAC.WesnesKA.Promethazine, scopolamine and cinnarazine: comparative time course of psychological performance effects.Psychopharmacology.1987925135193114803
   PubMed Web of Science ®Google Scholar
• WesnesKA.De l'utilité d'un modèle adéquat dans les essais médicamenteux à propos de la maladie d'Alzheimer.Patient Care.19941795104
   Google Scholar
• WesnesKA.O'NeillST.HollandRL.DonaldsonKM.The effects of scopolamine on spatial working memory and body sway.J Psychopharmacol.19959(suppl)A13
   Google Scholar
• WesnesKA.SimpsonPM.KiddAG.An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg.Hum Psychopharmacol.198832743
   Google Scholar
• EbertU.SiepmannM.OertelR.WesnesKA.KirchW.Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.J Clin Pharmacol.1998387207269725548
   PubMed Web of Science ®Google Scholar
• CarterWO.WilliamsSA.HiltonF.et al.The effects in man of nonselective anticholinergics on deoxyglucose metabolism in the brain.J Psychopharmacol.199913(suppl A)A28
   Google Scholar
• BarkerA.JonesR.PriorJ.WesnesKA.Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers: a 6-year follow-up.IntJ Geriatr Psychiatry.1998132442479646152
   PubMed Web of Science ®Google Scholar
• BarkerA.JonesR.SimpsonP.WesnesKA.Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers.int J Geriatr Psychiatry.19951010591062
   Web of Science ®Google Scholar
• WesnesKA.Cholinergic therapy directed at cognitive deficits. Symposium entitled: Molecular Pathology of Alzheimer's Disease.Eur Neuropsychopharrnacol.19966(suppl 3)2930
   Google Scholar
• WesnesKA.The pathology of attention of the dementias.J Psychopharmacol.199610(suppl)A51
   Google Scholar
• WesnesKA.The cognitive psychopharmacology of Alzheimer's disease.Psychopharmacol Bull.199632534
   Google Scholar
• WesnesKA.The extent of the involvement of cholinergic deterioration in the profile of cognitive impairment seen in Alzheimer's disease.Proc Br Psychol Soc.1996493
   Google Scholar
• WesnesKA.RevellA.The separate and combined effects of scopolamine and nicotine on human information processing.Psychopharmacology.1984845116436890
   PubMed Web of Science ®Google Scholar
• HallST.PuechA.SchafflerK.WesnesK.GamzuER.Group Report 3. Early clinical testing of cognition enhancers: prediction of efficacy.Pharmacopsychiatry.19902357602186414
   PubMed Web of Science ®Google Scholar
• WesnesKA.SimpsonPM.Can scopolamine produce a model of the memory deficits seen in ageing and dementia? In: Gruneberg MM, Morris PE, Sykes RN, eds.Practical Aspects of Memory: Current Research and issues. Volume 2. Clinical and Educational implications. Chichester, UK: John Wiley and Sons1988236242
   Google Scholar
• WesnesKA.The “scopolamine model of some core cognitive deficits seen in Alzheimer's disease”: same model, slightly different name.J Psychopharmacol.19959(suppl)A7
   Google Scholar
• WesnesKA.SimpsonP.WhiteL.PinkerS.The utility, validity and predictability of the scopolamine model of dementia.Clin Neuropharmacol.199215(suppl 1, part B)562
   Google Scholar
• WesnesKA.SimpsonPM.WhiteL.et al.Cholinesterase inhibition in the scopolamine model of dementia.Ann N Y Acad Sci.19916402682711776749
   PubMed Web of Science ®Google Scholar
• EbertU.OertelR.WesnesKA.KirchW.Effects of physostigmine on scopolamine-induced changes in quantitative electroencephalogram and cognitive performance.Hum Psychopharmacol.199813199210
   Web of Science ®Google Scholar
• SiegfriedKR.Pharmacodynamic and early clinical studies with velnacrine.Acta Neurol Scand Suppl.199314926288128834
   PubMedGoogle Scholar
• SiegfriedKR.The pharmacodynamics of velnacrine: results and conclusions from clinical studies in healthy subjects and patients with Alzheimer's disease. In: Wilcock GK, ed.The Management of Alzheimer's Disease. Petersfield, UK: Wrightson Biomedical Publishing1993189201
   Google Scholar
• WesnesKA.AnandR.SimpsonPM.ChristmasL.The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers.J Psychopharmacol.19904219232
   PubMedGoogle Scholar
• WesnesKA.SimpsonPM.KiddAG.The use of a scopolamine model to study the nootropic effects of tenilsetam (CAS 997) in man.Med Sci Res.19871510631064
   Google Scholar
• WesnesKA.AnandR.LorscheidT.Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of ageing and dementia.Acta Psychiatr Scand.1990827172
   Google Scholar
• JonesR.WesnesK.KirbyJ.Effects of NMDA modulation in scopolamine dementia.Ann N Y Acad Sci.19916402412441837979
   PubMed Web of Science ®Google Scholar
• WesnesKA.JonesRW.KirbyJ.The effects of 0-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia.Br J Clin Pharmacol.199131577578
   Google Scholar
• WesnesKA.RamezanlE.OliverS.FK960 antagonizes the memory impairments produced by scopolamine in healthy volunteers.J Psychopharmacol.199711(suppl)A57
   Google Scholar
• RapeportWG.ForsterP.McEwenJ.WesnesKA.The evaluation of candoxatril in the scopolamine model of dementia.Eur J Clin Invest.199525(suppl 2)A64
   Google Scholar
• NichollCG.LynchS.KellyCA.et al.The Cognitive Drug Research computerized assessment system in the evaluation of early dementia - is speed of the essence?int J Geriatr Psychiatry.199510199206
   Web of Science ®Google Scholar
• HollandRL.WesnesKA.Alzheimer's disease and other dementias. In: O'Grady J, Joubert PH, eds.Handbook of Phase l/II Clinical Drug Trials. Boca Raton, Fia: CRC Press1997355372
   Google Scholar
• WesnesKA.JenkinsEC.The locus of action of cholinergic blockade on attentional processing.J Psychopharmacol.199610(suppl)A51
   Google Scholar
• WesnesKA.Old and new treatments for new and old dementias.Proc Br Psychol Soc.19997141
   Google Scholar
• MohrE.WalkerD.RandolphC.SampsonM.MendisT.The utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia.int Psychogeriatr.199633974119116176
   PubMedGoogle Scholar
• WesnesKA.WarrenR.PittB.A comparison of the CAMCOG and the CDR system in a memory clinic population.J Psychopharmacol.199610(suppl)A29
   Google Scholar
• FerrisS.LuccaU.MohsR.et al.Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.Alzheimer Dis Assoc Disord.199711(suppl 3)34389305514
   PubMed Web of Science ®Google Scholar
• AllainH.WesnesKA.NeumanE.et al.Acceptability and clinical activity of 4 weeks treatment by S12024-2 in 53 in-patients with moderate-tosevere Alzheimer's disease.Neurobiol Aging.19941551365137
   Web of Science ®Google Scholar
• FakouhiTD.JheeSS.SramekJJ.et al.Evaluation of cycloserine in the treatment of Alzheimer's disease.J Geriatr Psychiatry Neurol.199582262308561836
   PubMed Web of Science ®Google Scholar
• MohrE.KnottV.SampsonM.WesnesKA.HertingR.MendisT.Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease.Clin Neuropsychopharrnacol.1995182338
   PubMed Web of Science ®Google Scholar
• WesnesKA.ScottM.BoyleM.SurmonDJ.WilcockGK.Use of the Cognitive Drug Research computerized assessment system to measure the efficacy of THA and galanthamine in Alzheimer's disease.Psychopharmacol Bull.199430139
   Google Scholar
• SiegfriedK.A placebo-controlled crossover study of velnacrine in patients with Alzheimer's disease.Neurology.199242(suppl 3)1411574170
   PubMedGoogle Scholar
• WesnesKA.ScottM.MorrisonS.GreenwoodD.Russell-DuffK.WilcockGK.The effects of galanthamine on attention in Alzheimer's disease.J Psychopharmacol.199812(suppl A)A46
   Google Scholar
• AyreG.BallardC.PincockC.McKeithI.SahgalA.WesnesKA.Double dissociation between dementia with Lewy bodies and Alzheimer's disease on tests of attentional and mnemonic function: the role of the basal forebrain.J Psychopharmacol.199812(suppl A)A41
   Google Scholar
• AyreGA.SahgalA.McKeithIG.et al.Distinct profiles of neuropsychological impairment in dementia with Lewy bodies and Alzheimer's disease.Neurology. 2000. In press.
   PubMedGoogle Scholar
• AyreG.McKeithIG.SahgalA.BallardCG.WesnesKA.The profile of cognitive deterioration in Lewy body dementia.Proc Br Psychol Soc.1997548
   Google Scholar
• McKeithIG.AyreGA.PincockC.et al.The relative impairment of attentional and secondary memory function distinguishes dementia with Lewy bodies and Alzheimer's disease.Neurobiol Aging.199819(suppl 2)S206
   Google Scholar
• PapkaM.SchifferR.ValoneC.A prospective study of Lewy body disease.J Neuropsychiatry Clin Neurosci.199911141142
   Google Scholar
• AyreGA.McKeithIG.SahgalA.BallardCG.WesnesKA.Dementia with Lewy bodies, Alzheimer's disease and vascular dementia show distinct patterns of cognitive impairment.J Psychopharmacol.199711(suppl)A56
   Google Scholar
• AyreG.BallardC.PincockC.WesnesKA.McKeithI.SahgalA.Association between visual hallucinations, neurochemical pathology and cognition in dementia with Lewy bodies.J Psychopharmacol.199812(suppl A)A64
   Google Scholar
• WalkerMP.AyreGA.AshtonCH.et al.A psychophysiological investigation of fluctuating consciousness in neurodegenerative dementias.Hum Psychopharmacol.199914483489
   Web of Science ®Google Scholar
• WesnesKA.Predicting, assessing, differentiating and treating the dementias: experience in MCI and various dementias using the CDR computerized cognitive assessment system. In: Vellas B, Fitten LJ, eds.Research and Practice in Alzheimer's disease.2000Vol 3. Paris, France: Serdi5965
   Google Scholar
• HunterR.CameronS.PerksS.WesnesKA.The cognitive profile of unmedicated schizophrenic patients in relation to controls.J Psychopharmacol.199711(suppl)A74
   Google Scholar
• ScholeyA.McCueP.WesnesKA.A comparison of the cognitive deficits seen in myalgic encephalomyelitis to Alzheimer's disease.Proc Br Psychol Soc.1999712
   Google Scholar
• BlackK.ScholeyA.AyreGA.WesnesKA.A computerized cognitive assessment of multiple sclerosis.Proc Br Psychol Soc.19997119
   Google Scholar
• ScholeyAB.BlackK.AyreGA.WesnesKA.Cognitive deficits in multiple sclerosis: a computerized assessment.J Psychopharmacol.199913(suppl A)A29
   Google Scholar
• RobertsN.PincockC.WesnesKA.Some cognitive effects of hyperthyroidism.J Psychopharmacol.199711(suppl)A61
   Google Scholar
• ParrySW.McCueP.AyreGA.StoutNR.WesnesKA.KennyRA.Cognition is impaired in elderly fallers with carotid sinus syndrome (CSS).J Psychopharmacol.199913(suppl A)A29
   Google Scholar
• ParrySW.McCueP.AyreGA.WesnesKA.StoutNR.KennyRA.Cognitive function in older patients with carotid sinus hypersensitivity is impaired compared with age-matched healthy controls.Age Ageing.1999. In press.
   Google Scholar
• FearnSJ.PictonAJ.WesnesKA.ParryAN.McCollumCN.Cognitive function following carotid endarterectomy.Cerebrovasc Dis.19977(suppl 4)25
   Google Scholar
• FearnSJ.WesnesKA.PictonAJ.ParryAD.O'NeillST.McCollumCNThe influence of carotid endarterectomy on cognitive function.J Psychopharmacol.199711(suppl)A59
   Google Scholar
• SaxbyBK.HarringtonF.PoppletonH.et al.Cognitive performance in normotensive and hypertensive older subjects.J Psychopharmacol.1999130(suppl A)A29
   Google Scholar
• RobinsonR.StantonJ.WisemanW.et al.Computerized cognitive testing of cardiovascular patients.Biol Psychiatry.199129482S
   Google Scholar
• TakkenbergJ.OudenaardeI.van der VeldenE.ChalfontL.WesnesKA.van HerwerdenL.Neuropsychologic dysfunction after CABG: standard cardiopulmonary bypass versus MICAB.J Psychopharmacol.199913(suppl A)A56
   Google Scholar
• MeadGE.WesnesKA.ShinglerH.McCollumCN.O'NeillPAComputerized assessment of cognitive function in acute stroke.J Psychopharmacol.199711(suppl)A59
   Google Scholar
• KeithMS.StanislavSW.WesnesKA.Validity of a cognitive computerized assessment system in brain-injured patients.Brain injury.199812103710439876863
   PubMed Web of Science ®Google Scholar
• MoffatN.LawsonC.Computerized neuropsychological assessment after minor head injury and after carbon monoxide poisoning.Proc Br Psychol Soc.19964115
   Google Scholar
• WesnesKA.FearnSJ.O'NeillST.McCollumCN.Cognitive function prior to coronary artery bypass or carotid endarterectomy: the role of diabetes.J Psychopharmacol.199711(suppl)A59
   Google Scholar
• WesnesKA.WalkerLG.WalkerMB.et al.What does a weekend “oncall” in a surgical oncology unit do to cognitive performance and mood?Br J Surg.1996844934959112899
   PubMed Web of Science ®Google Scholar
• RitchieKA.MacdonaldE.HammersleyR.et al.A pilot study of the effect of low level exposure to mercury on the health of dental surgeons.Occup Environ Med.1995528138178563844
   PubMed Web of Science ®Google Scholar
• NaylorL.PincockC.WesnesKA.Organic solvent exposure and cognitive impairment.J Psychopharmacol.199610(suppl)A29
   Google Scholar
• ParrottAC.LeesA.GarnhamNJ.JonesM.WesnesKA.Cognitive performance in recreational users of MDMA or “ecstasy”: evidence for memory deficits.J Psychopharmacol.19981279839584971
   PubMed Web of Science ®Google Scholar
• PreeceAW.WesnesKA.IwiG.The effect of a 50-Hz magnetic field on cognitive function in humans.int J Radiat Biol.1998744634709798957
   PubMed Web of Science ®Google Scholar
• PreeceAW.IwiG.Davies-SmithA.et al.Effect of a 915-MHz simulated mobile phone signal on cognitive function in man.Int J Radiat Biol.19997544745610331850
   PubMed Web of Science ®Google Scholar
• O'NeillWM.HanksGW.SimpsonPM.WesnesKA.The utility of computerized cognitive assessments in patients taking opioids for cancer pain.Eur J Clin invest.199525(suppl 2)A65
   Google Scholar
• WalkerLG.WalkerMB.HeysSD.LolleyJ.WesnesKA.EreminO.The psychological and psychiatric effects of rIL-2: a controlled trial.Psychooncology.199762903019451748
   PubMed Web of Science ®Google Scholar
• WalkerLG.WesnesKA.HeysSD.WalkerMB.LolleyJ.EreminO.The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerized assessments.Eur J Cancer.199632(suppl A)227522839038610
   PubMedGoogle Scholar
• ThompsonJM.NeaveN.MossMC.ScholeyA.WesnesKA.GirdlerNM.Cognitive properties of sedation agents: comparison of the effects of nitrous oxide and midazolam on memory and mood.Br Dental J.1999187557562
   PubMed Web of Science ®Google Scholar
• BailieR.ChristmasL.PriceN.RestallJ.SimpsonPM.WesnesK.Effects of temazepam pre-medication on cognitive recovery following alfentanil/propofol anaesthesia.Br J Anaesthesiol.1989636875
   PubMed Web of Science ®Google Scholar
• ScholeyA.MackayI.McCueP.MossM.WesnesKA.Oxygen administration reverses cognitive deficits associated with chronic fatigue syndrome.Proc Br Psychol Soc.19997110
   Google Scholar
• WesnesKA.SimpsonPM.WhiteL.LeekC.KatonaC.The cognitive effects of moclobemide and nortriptyline in elderly, depressed patients. Annual Meeting of the British Association for Psychopharmacology. Cambridge, UK. 1994 7
   Google Scholar
• HearingS.BowmanC.WesnesK.Beta-blockers and cognitive function in elderly hypertensive patients: withdrawal and consequences of ACE inhibitor substitution.int J Geriatr Psychopharmacol.199921317
   Google Scholar
• WesnesKA.SimmonsD.RookM.SimpsonPM.A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly.Hum Psychopharmacol.19872159171
   Google Scholar
• RaiGS.ShovlinC.WesnesKA.A double-blind, placebo-controlled study of Gingko biloba extract (“Tanakan”) in elderly out-patients with mild-to-moderate memory impairment.Curr Med Res Opin.1991123503552044394
   PubMed Web of Science ®Google Scholar
• WesnesKA.FaleniRA.HeftingNR.et al.The cognitive subjective and physical effects of a Ginkgo biloba/Panax ginseng combination in healthy volunteers with neurasthenic complaints.Psychopharmacol Bull.1997336776839493479
   PubMedGoogle Scholar
• WaddingtonG.WardT.RotherhamN.EnglerJ.HermanC.WesnesKA.The development and validation of a technique for administering cognitive tests over the telephone.J Psychopharmacol.199913(suppl A)A26
   Google Scholar
• WesnesKA.WardT.AyreG.PincockC.Development and validation of a system for evaluating cognitive functioning over the telephone for use in late phase drug development.Eur Neuropsychopharrnacol.19999(suppl 5)S368
   Google Scholar